| Identification | Back Directory | [Name]
L-Proline, compd. with 2-[(4-cyclopropylphenyl)methyl]-4-β-D-glucopyranosylbenzonitrile (1:1) | [CAS]
1539295-26-5 | [Synonyms]
Velagliflozin (proline) | [Molecular Formula]
C23H25NO5.C5H9NO2 | [MOL File]
1539295-26-5.mol | [Molecular Weight]
510.58 |
| Hazard Information | Back Directory | [Uses]
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1]. | [in vivo]
Velagliflozin (1 mg/kg; p.o.; single dose) proline increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats[1].
Velagliflozin (0.3 mg/kg; p.o.; once daily for 18 d) proline is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC)[2].
| [References]
[1] Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273. DOI:10.1111/jvp.12467
[2] Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655. DOI:10.1371/journal.pone.0203655 |
|
|